Hims & Hers Is Trying To Make Healthcare Feel Like Shopping Online
TL;DR
Quick Summary
- Hims & Hers has grown into a roughly $6.5B telehealth-and-e‑commerce hybrid by turning awkward health issues into subscription services.
- Revenue grew close to 50% year over year in Q3 2025 to about $600M, with rising cash flow but some pressure on margins.
- After a run toward $73 and a sharp pullback to the high‑$20s by January 2026, the stock is in "prove it" mode on new growth areas and regulatory risk.
- The next leg of the story hinges on execution in weight loss, hormone health, diagnostics, and international expansion – not just good branding.
- Many investors already own HIMS indirectly via broad and thematic ETFs like VTI, VTSAX, and EDOC.
You've reached your free daily article limit (1/1).
Create a free account to get unlimited access to all articles, market insights, and more.
Register for FreeAlready have an account? Sign in
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
